Edwards Lifesciences Sees Q4 EPS $0.53-$0.57; Sales $1.33B-$1.39B
Portfolio Pulse from Benzinga Newsdesk
Edwards Lifesciences has provided guidance for Q4, expecting EPS between $0.53 and $0.57 and sales between $1.33 billion and $1.39 billion.
October 24, 2024 | 8:25 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Edwards Lifesciences has issued Q4 guidance with EPS expected between $0.53 and $0.57 and sales between $1.33 billion and $1.39 billion.
The guidance provided by Edwards Lifesciences is within a typical range and does not indicate any significant deviation from expectations. This suggests a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100